CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting
November 01, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021
October 28, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces New Employment Inducement Grants
October 18, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors
October 04, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces New Employment Inducement Grants
September 16, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces New Employment Inducement Grants
August 17, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 16:15 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)
August 04, 2021 08:00 ET
|
CytomX Therapeutics Inc.
-Translational whole-body PET clinical imaging supports conditional activation in the tumor microenvironment- -Pacmilimab demonstrated single-agent activity in advanced solid tumors, including...
CytomX Therapeutics to Present at Upcoming August Investor Conferences
August 02, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...